Faith Zaslavsky

President & Chief Executive Officer

Ms. Zaslavsky currently serves as President and Chief Executive Officer at Theralink. Prior to Theralink, Ms. Zaslavsky served as President of Oncology for a life sciences company. Her responsibilities have included overseeing all commercials functions which include leading Medical Services, Medical Affairs, National and Enterprise Accounts, and Sales and Marketing.  She has spent 22 years leading and transforming teams, designing solutions for physicians to support care, and advocating for patients facing a journey with cancer.

She also serves on the American Society of Breast Surgeons Foundation Board of Directors. Ms. Zaslavsky also loves to invest time in improving opportunities for our youth as she has coached USATF for elementary age children, sat on the board for Northwest TaeKwonDo and currently is an active member of the Solomon Schechter Board.


Chief Financial Officer

Andrew “Al” Kucharchuk currently serves as Chief Financial Officer at Theralink. He has a proven ability to increase the overall financial health of a company by reducing costs, improving internal controls and overall efficiency management. Al is proficient in tax and regulatory compliance, budgeting and forecasting, internal controls, auditing, corporate strategy, SEC filings, financial analysis, and equity and debt financings.

Over the past 13 years, Mr. Kucharchuk has held various positions at OncBioMune–specifically CEO, President and CFO. He has directed all business efforts, oversaw all financial and administrative processes, managed all government relationships and was responsible for an international acquisition.

Al received his Bachelor’s degree from Louisiana State University and his MBA with a finance concentration from Tulane University.

Mick Ruxin, M.D.

Chief Medical Officer and Director

Dr. Ruxin, who is the Chief Medical Officer of Theralink Technologies, had initially been a strategic advisor to the Company starting in December 2017. Previously Dr. Ruxin was the Chairman, CEO, and Founder of Global Med Technologies, Inc. (GLOB).

He grew GLOB from a foundational concept to an international medical software company, specializing in FDA approved software, with specific diagnostic capabilities, and serving over 30 countries on 4 continents. Under his leadership, GLOB had its initial financing, its public offering and subsequent follow-on financings.

Dr. Ruxin also founded PeopleMed, Inc., a validation and chronic disease management software subsidiary of GLOB. In addition, he conceived and executed the acquisition and financing of Inlog, a French software company serving the EU, becoming the Directeur General and responsible for European Operations, and eDonor, a US based regulated software company serving domestic and international blood donor centers.

Prior to Dr. Ruxin engineering the sale of GLOB to a NYSE company, Haemonetics Corp. (HAE), he led his team to national prominence by being awarded the #1 position in quality of product and customer service against billion dollar software companies, rated by an industry-respected, independent software rating service.

After GLOB’s acquisition by Haemonetics, Dr. Ruxin was asked to stay with the company through the transition. Dr. Ruxin was on the Executive Management Team (EMT) at Haemonetics for approximately 6 months after the merger. The EMT was responsible for diagnostic strategies and identified domestic and international software opportunities for the Company.

Before founding Global Med Technologies, Dr. Ruxin founded and was President and CEO of DataMed International, Inc. (DMI), a private, international drugs of abuse management company (from 1989-1997). DMI’s clients included FedEx, International Multi-Foods, Los Alamos National Laboratories, Chevron, ConAgra, Nestles and AT&T, among over 500 other companies.

Dr. Ruxin was one of the first 10 certified Medical Review Officers in the country, and he participated in writing the Federal legislation for drugs of abuse testing. Dr. Ruxin received his M.D. degree from the University of Southern California and his B.A degree in Philosophy from the University of Pittsburgh.

Justin Davis, Ph.D.

VP, Research and Development

Justin Davis currently serves as the Laboratory Director at Theralink Technologies. Justin earned his Ph.D. in Biochemistry from George Mason University.

He continued as a Post-Doctoral Research Fellow, and later, as a Research Assistant Professor at the Center for Applied Proteomics and Molecular Medicine under Drs. Lance Liotta and Chip Petricoin. Justin’s research interests have centered on the RPPA technology and protein signaling, with publications spanning topics of glioblastoma tumor heterogeneity, small molecule induction of glial neurotrophin secretion, and evolving RPPA technology and its applications.

Mattia Cremona, Ph.D.

Lab Director

Mattia Cremona, Ph.D. joined Theralink Technologies as Director of its Biopharma Laboratory in November 2022. Dr. Cremona is an experienced research scientist with a Ph.D. in molecular medicine from Università degli Studi di Milano and a higher diploma in biopharmaceutical and medical device manufacturing from TU Dublin.

After a post-doctoral fellowship at the Center for Applied Proteomics under Drs. Lance Liotta and Chip Petricoin, he established and ran the first RPPA facility in Ireland. Prior to Theralink, he worked in world-leading research hospitals and universities in Europe and the USA.

During his career, Dr. Cremona focused on high throughput immuno-based assays to identify the proteomic profile of tumor samples and to evaluate the response/resistance to drug treatments.

Claudius Mueller

Director of Bioinformatics

Claudius Mueller is the Director of Bioinformatics at Theralink Technologies. He served as a consultant to the company since 2018 before joining in his current position in August 2021. Claudius earned is Diploma in Biochemistry from the Freie Universität Berlin, Germany, and his Ph.D. in Biochemistry from Loma Linda University, USA.

Claudius worked as a Post-Doctoral Research Fellow, Research Assistant Professor, and Research Associate Professor at George Mason University (GMU) within the Center for Applied Proteomics and Molecular Medicine under the leadership of Drs. Lance Liotta and Chip Petricoin.

During his career, Claudius authored more than 40 peer-reviewed publications and book chapters. He developed software for RPPA, Mass Spectrometry, ELISA, and PCR data analysis for GMU and international research groups. Claudius also created a Covid data processing App that was used within the university’s CAP/CLIA accredited Clinical Proteomics laboratory to analyze more than 50,000 Covid samples during Covid screening.

His research interests include tumor clonal heterogeneity, cancer cell signal transduction, Alzheimer’s disease, and the preservation of labile tissue biomarkers.

Trevor McCartney

VP, Sales Operations and Strategic Partnerships

Trevor is the VP, Sales Operations and Strategic Partnerships for Theralink Technologies. He has 20+ years of cancer leadership experience working in the field of enabling technologies for cancer care and is excited to now be leading the charge for Theralink in proteomic-based, personalized medicine that empowers oncologists, cancer patients and their families.

Prior to Theralink, Trevor worked in various capacities with Elekta Inc., a global provider of medical devices for the treatment of cancer and brain disorders, culminating in his appointment as Senior Director of Elekta Canada. In this role, he was responsible for all of Elekta’s Business Development in Canada.

Prior to his work with Elekta, Trevor was the Senior Vice President of Sales and Marketing at OpTx Corporation, a company that created the world’s first oncology-specific electronic medical record and decision support system. He helped develop the company into an international healthcare services and technology company before its eventual sale to Varian Medical Systems, itself a leading supplier of medical devices for radiation therapy in the oncology community.

Prior to OpTx, Trevor was a Sales Executive with IBM holding various leadership positions from 1984 through 1996.

Mike Vallone

Senior Director of Commercialization

Mike spent 15 years with an industry leader in the field of genetics, establishing a track record of success in both sales and leadership roles within the organization. As a leader, Mike was involved with several key initiatives within the Oncology business unit, including the successful launch of 6 new products. Mike was also an integral part of several key collaborations within the Oncology business unit, from developing sales training content to strategizing with Sales Operations for business planning and sales goals.  Mike also worked closely with Human Resources to establish account executive development and promotion criteria for the Oncology division within the organization.

In addition, he is a 4x President Club winner, a 6x MVP award recipient, and earned multiple promotions due to his performance and outstanding contributions to the organization. Mike also has expansive understanding of managed care, having spent more than 7 years working for one of the largest managed care companies in the country in the area of provider relations and contracting. With these experiences, Mike is extremely excited to help bring awareness and education of Theralink’s products to ordering physicians to help guide them to better treatment decisions for improved patient care.

Consultants to the Management Team

Lance Liotta, M.D., Ph.D.

Medical Advisory Board Chairman

Dr. Lance Liotta has served as Co-Director and Co-Founder of the Center for Applied Proteomics and Molecular Medicine (CAPMM) at George Mason University since 2005. Prior to this appointment, Dr. Liotta served as Chief of the Laboratory of Pathology, NCI, Deputy Director of NIH, Co-Director of the NCI/FDA Clinical Proteomics Program, and Director of the Anatomic Pathology Residency Program.

At the NIH he went on to investigate the process of tumor invasion and metastasis at the molecular level (MMP2, and TIMP2). He was the first to describe tumor cell invasion of the basement membrane (3-step hypothesis) and the role of tumor cell pseudopodia in tumor cell invasion. Dr. Liotta has invented and patented, along with his laboratory co-inventors, transformative technologies in the fields of diagnostics, cancer molecular therapeutics, Laser Capture Microdissection, and proteomics (Reverse Phase Protein Microarrays, Biomarker Harvesting Nanoparticles, preservation chemistries for molecular analysis, and “protein painting” for drug target mapping) that have been used to make broad discoveries in cancer biology, and diagnostics, and therapeutics.

The Laser Capture Microdissection prototype is in the Smithsonian Collection. He is a co-founder of Theranostics Health and Ceres Nanosciences. Dr. Liotta has more than 100 issued or allowed patents and more than 700 publications.

He is an ISI highly cited investigator and the recipient of numerous awards for biomedical research including the 2015 Outstanding Virginia Faculty Award (SCHEV), the Flemming Award for Cancer Research, the Warner-Lambert Parke Davis Award, and the Surgeon General’s Medallion. He is Board Certified in Anatomic Pathology and is Medical Director of the GMU CAP/CLIA certified clinical proteomics Lab.

Emanuel F. Petricoin, Ph.D.

Scientific Advisory Board Chairman

Dr. Emanuel F. Petricoin has been the Co-Director of the Center for Applied Proteomics and Molecular Medicine (CAPMM) at George Mason University since 2005, where he is a University Professor. The focus of the CAPMM is the invention and use of proteomics technologies for personalized therapy, molecular diagnostics and biomarker discovery.

He is a co-founder of four life science companies in the nanotechnology-diagnostic and precision medicine space. He has co-authored nearly 400 publications, and is a co-inventor on 40 filed and published patents.

He has authored over 45 book chapters, is a Senior Editor for Cancer Epidemiology Biomarkers and Prevention and on the editorial board of JCO Precision Oncology, Nature Precision Oncology, Proteomics, Biomedical Microdevices, Proteomics-Clinical Applications, Proteomics-Protocols, Molecular, Carcinogenesis and the Journal of Personalized Medicine. Dr. Petricoin is a founding member of the Human Proteomic Organization (HUPO).

He has received numerous awards including the University Professorship at George Mason University, the NIH Director’s Award, FDA Distinguished Scientist Award, 2015 Innovator of the Year Award, GAP50 Top Virginia Entrepreneurs, Nifty 50 Award, American Society of Cytopathology Basic Research Award, the Roche Diagnostics/CLAS Distinguished Scientist Award and the Harvard University Leading Edge Award. Dr. Petricoin has been awarded the distinction of a Kentucky Colonel.

Virginia Espina, Ph.D.

Virginia (Ginny) Espina, PhD, is a Research Associate Professor at George Mason University in the Center for Applied Proteomics and Molecular Medicine. Dr. Espina is the technical director and manager of the CAP/CLIA accredited Clinical Proteomics laboratory.

She received her BS in Medical Technology from Rochester Institute of Technology, an MS in Biotechnology from Johns Hopkins University, and a PhD in Biosciences from George Mason University. She has strong operations management, technical, and regulatory skills with over 20 years’ experience in clinical and academic research labs.

Dr. Espina designs and performs basic/translational research studies and human clinical trials, which focus on elucidating potential therapeutic targets in the tissue microenvironment for cancer and infectious diseases. Since 2002, her translational research projects have resulted in 6 issued patents, in the areas of tissue preservation, mechanisms of development/treatment of premalignant lesions, and novel diagnostic technologies.

Her work has led to the widespread adoption of reverse phase protein array and laser capture microdissection for personalized medicine. Dr. Espina is frequently an invited speaker at technology workshops and international conferences. Dr. Espina is on the editorial board of Molecular and Cellular Proteomic and serves as a peer reviewer for several journals.

Dr. Espina is an author of more than 100 peer-reviewed publications and editor of Molecular Profiling in the Methods in Molecular Biology series. She is a member of the American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), American Thyroid Association (ATA), American Society for Cell Biology (ASCB), American Society for Biochemistry and Molecular Biology (ASBMB), and American Society for Clinical Pathology (ASCP). Dr. Espina is a board certified Medical Technologist (ASCP).